718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells

718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells

Bibliographic Details
Main Authors: Cong Li, Gregory Moore, Umesh Muchhal, John Desjarlais, Matthew Bernett, Madeline Fort, Lingming Liang, Tao Osgood, Rodolfo Yabut, Sarav Kaliyaperumal, John Harrold, Jude Canon, Anna Rogojina, Raushan Kurmasheva, Peter Houghton, Olivier Nolan-Stevaux
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer
id doaj-9f44cfaebbde4a72a66c6cbe35d25b0b
record_format Article
spelling doaj-9f44cfaebbde4a72a66c6cbe35d25b0b2020-12-11T10:03:37ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0718718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cellsCong Li0Gregory Moore1Umesh Muchhal2John Desjarlais3Matthew Bernett4Madeline Fort5Lingming Liang6Tao Osgood7Rodolfo Yabut8Sarav Kaliyaperumal9John Harrold10Jude Canon11Anna Rogojina12Raushan Kurmasheva13Peter Houghton14Olivier Nolan-Stevaux1Amgen Inc., South San Francisco, CA, USAXencor, Inc., Monrovia, CA, USAAff390 Xencor, Inc. Monrovia CA USA Aff390 Xencor, Inc. Monrovia CA USA Xencor, Inc., MONROVIA, CA, USA1Amgen Inc., South San Francisco, CA, USA1Amgen Inc., South San Francisco, CA, USA1Amgen Inc., South San Francisco, CA, USA1Amgen Inc., South San Francisco, CA, USA1Amgen Inc., South San Francisco, CA, USA1Amgen Inc., South San Francisco, CA, USA1Amgen Inc., South San Francisco, CA, USA3University of Texas Health San Antonio, San Antonio, TX, USA3University of Texas Health San Antonio, San Antonio, TX, USA3University of Texas Health San Antonio, San Antonio, TX, USA
collection DOAJ
language English
format Article
sources DOAJ
author Cong Li
Gregory Moore
Umesh Muchhal
John Desjarlais
Matthew Bernett
Madeline Fort
Lingming Liang
Tao Osgood
Rodolfo Yabut
Sarav Kaliyaperumal
John Harrold
Jude Canon
Anna Rogojina
Raushan Kurmasheva
Peter Houghton
Olivier Nolan-Stevaux
spellingShingle Cong Li
Gregory Moore
Umesh Muchhal
John Desjarlais
Matthew Bernett
Madeline Fort
Lingming Liang
Tao Osgood
Rodolfo Yabut
Sarav Kaliyaperumal
John Harrold
Jude Canon
Anna Rogojina
Raushan Kurmasheva
Peter Houghton
Olivier Nolan-Stevaux
718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells
Journal for ImmunoTherapy of Cancer
author_facet Cong Li
Gregory Moore
Umesh Muchhal
John Desjarlais
Matthew Bernett
Madeline Fort
Lingming Liang
Tao Osgood
Rodolfo Yabut
Sarav Kaliyaperumal
John Harrold
Jude Canon
Anna Rogojina
Raushan Kurmasheva
Peter Houghton
Olivier Nolan-Stevaux
author_sort Cong Li
title 718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells
title_short 718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells
title_full 718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells
title_fullStr 718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells
title_full_unstemmed 718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells
title_sort 718 amg 509, a steap1 x cd3 bispecific xmab® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high steap1-expressing prostate and ewing sarcoma cancer cells
publisher BMJ Publishing Group
series Journal for ImmunoTherapy of Cancer
issn 2051-1426
publishDate 2020-11-01
work_keys_str_mv AT congli 718amg509asteap1xcd3bispecificxmab21immunetherapyexhibitsaviditydrivenbindingandpreferentialkillingofhighsteap1expressingprostateandewingsarcomacancercells
AT gregorymoore 718amg509asteap1xcd3bispecificxmab21immunetherapyexhibitsaviditydrivenbindingandpreferentialkillingofhighsteap1expressingprostateandewingsarcomacancercells
AT umeshmuchhal 718amg509asteap1xcd3bispecificxmab21immunetherapyexhibitsaviditydrivenbindingandpreferentialkillingofhighsteap1expressingprostateandewingsarcomacancercells
AT johndesjarlais 718amg509asteap1xcd3bispecificxmab21immunetherapyexhibitsaviditydrivenbindingandpreferentialkillingofhighsteap1expressingprostateandewingsarcomacancercells
AT matthewbernett 718amg509asteap1xcd3bispecificxmab21immunetherapyexhibitsaviditydrivenbindingandpreferentialkillingofhighsteap1expressingprostateandewingsarcomacancercells
AT madelinefort 718amg509asteap1xcd3bispecificxmab21immunetherapyexhibitsaviditydrivenbindingandpreferentialkillingofhighsteap1expressingprostateandewingsarcomacancercells
AT lingmingliang 718amg509asteap1xcd3bispecificxmab21immunetherapyexhibitsaviditydrivenbindingandpreferentialkillingofhighsteap1expressingprostateandewingsarcomacancercells
AT taoosgood 718amg509asteap1xcd3bispecificxmab21immunetherapyexhibitsaviditydrivenbindingandpreferentialkillingofhighsteap1expressingprostateandewingsarcomacancercells
AT rodolfoyabut 718amg509asteap1xcd3bispecificxmab21immunetherapyexhibitsaviditydrivenbindingandpreferentialkillingofhighsteap1expressingprostateandewingsarcomacancercells
AT saravkaliyaperumal 718amg509asteap1xcd3bispecificxmab21immunetherapyexhibitsaviditydrivenbindingandpreferentialkillingofhighsteap1expressingprostateandewingsarcomacancercells
AT johnharrold 718amg509asteap1xcd3bispecificxmab21immunetherapyexhibitsaviditydrivenbindingandpreferentialkillingofhighsteap1expressingprostateandewingsarcomacancercells
AT judecanon 718amg509asteap1xcd3bispecificxmab21immunetherapyexhibitsaviditydrivenbindingandpreferentialkillingofhighsteap1expressingprostateandewingsarcomacancercells
AT annarogojina 718amg509asteap1xcd3bispecificxmab21immunetherapyexhibitsaviditydrivenbindingandpreferentialkillingofhighsteap1expressingprostateandewingsarcomacancercells
AT raushankurmasheva 718amg509asteap1xcd3bispecificxmab21immunetherapyexhibitsaviditydrivenbindingandpreferentialkillingofhighsteap1expressingprostateandewingsarcomacancercells
AT peterhoughton 718amg509asteap1xcd3bispecificxmab21immunetherapyexhibitsaviditydrivenbindingandpreferentialkillingofhighsteap1expressingprostateandewingsarcomacancercells
AT oliviernolanstevaux 718amg509asteap1xcd3bispecificxmab21immunetherapyexhibitsaviditydrivenbindingandpreferentialkillingofhighsteap1expressingprostateandewingsarcomacancercells
_version_ 1724386589019209728

Similar Items